Potential role of circulating miRNAs as biomarkers in solid tumor

 
crossMark
 
Journal of Cellular Cancer  Volume 6, Issue 2, pages 39-57
Published: December 11, 2014


Jung Zhang, Kai-Li Feng,Ting Wang, Shan Young-Kyun, Liu Yan, Chung Tae-Young  

Abstract

MiRNAs modulate the expression of tumor suppressor genes as well as oncogenes. The identification of stable miRNAs in bodily fluids paved the way for their use as novel biomarkers amenable to clinical diagnosis in translational medicine. Identification of miRNAs in exosomes that are functional upon delivery to the recipient cells has highlighted a novel method of intercellular communication. In the present review, we focus on recent advancements in the discovery and development of miRNA-based cancer therapeutics using these 2 approaches. In addition, we summarize selected studies, in which modulation of miRNA activity in preclinical cancer models in vivo has demonstrated promising therapeutic potential.

Keywords: MiRNAs; Cancer; Oncogenes; Preclinical cancer models

Purchase access to this articleReferencesExport Citation
Purchase this article at rate $55.00 and received Full-Text/PDF You will have online immediate access to article following the completion of this purchase and you may download and print a copy of each article for your personal use. Purchase Article

References

  1. Hur C, Miller M, Kong CY, et al. Trends in esophageal adenocarcinoma incidence and mortality. Cancer 2013;119:1149-1159. [CrossRef][ Web of Science][Medline]
  2. Mathers CD, Fat DM, Inoue M, Rao C, Lopez AD. Counting the dead and what they died from: an assessment of the global status of cause of death data. Bull World Health Organ 2005;83:171-177. [PubMed]
  3. Doll R, Cook P. Summarizing indices for comparison of cancer incidence data. Int J Cancer 1967;2:269-279. [Abstract]
  4. Bray F, Moller B. Predicting the future burden of cancer. Nat Rev Cancer 2006;6:63-74. [CrossRef][PubMed]
  5. Howson CP, Hiyama T, Wynder EL. The decline in gastric cancer: epidemiology of an unplanned triumph. Epidemiol Rev 1986;8:1-27. [PubMed]
  6. London WT, McGlynn KA. Liver cancer. In: Schottenfeld D, Fraumeni J Jr, eds. Cancer Epidemiology and Prevention. 3rd ed. New York: Oxford University Press; 2006:763-786.
  7. Lupardus PJ, Birnbaum ME, Garcia KC. Molecular basis for shared cytokine recognition revealed in the structure of an unusually high affinity complex between IL-13 and IL-13Ralpha2. Structure 2010; 18:332–342. [PubMed/NCBI]
  8. Debinski W, Gibo DM, Slagle B, Powers SK, Gillespie GY. Receptor for interleukin 13 is abundantly and specifically over-expressed in patients with glioblastoma multiforme. Int J Oncol 1999;15:481–486. [PubMed/NCBI]
  9. Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med 2006;12: 99–106. [PubMed/NCBI]
  10. Fichtner-Feigl S, Young CA, Kitani A, et al. IL-13 signaling via IL-13R alpha2 induces major downstream fibrogenic factors mediating fibrosis in chronic TNBS colitis. Gastroenterology 2008;135: 2003–2013.
  11. Yousif NG. Fibronectin promotes migration and invasion of ovarian cancer cells through up-regulation of FAK-PI3K/Akt pathway. Cell Biol Int 2014;38(1):85-91. [PubMed]
  12. Ferlay J, Soerjomataram I, Ervik M, et al. International Agency for Research on Cancer. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. [globocan.iarc.fr.]
  13. Strober W, Kitani A, Fichtner-Feigl S, Fuss IJ. The signaling function of the IL-13Ralpha2 receptor in the development of gastrointestinal fibrosis and cancer surveillance. Curr Mol Med 2009;9:740–750. [PubMed]
  14. Parkin DM. The evolution of the population-based cancer registry. Nat Rev Cancer 2006;6:603-612. [PubMed]
  15. Parkin DM, Nambooze S, Wabwire-Mangen F, Wabinga HR. Changing cancer incidence in Kampala, Uganda, 1991-2006. Int J Cancer 2010;126:1187-1195. [PubMed]
  16. Krishnamurthy M, Li J, Fellows GF, et al. Integrin {alpha}3, but not {beta}1, regulates islet cell survival and function via PI3K/Akt signaling pathways. Endocrinology 2011;152(2) 424–35. [PubMed/NCBI]
  17. Lee AW, Foo W, Mang O, et al. Changing epidemiology of nasopharyngeal carcinoma in Hong Kong over a 20-year period (1980-99): an encouraging reduction in both incidence and mortality. Int J Cancer 2003;103:680-685. [Abstract][Full Article (HTML)][PDF(90K)]
  18. Yahagi N, Kosaki R, Ito T, et al. Position-specific expression of Hox genes along the gastrointestinal tract. Congenit Anom (Kyoto) 2004; 44:18–26. [PubMed/NCBI]
  19. Chen KN, Gu ZD, Ke Y, Li JY, Shi XT, Xu GW. Expression of 11 HOX genes is deregulated in esophageal squamous cell carcinoma. Clin Cancer Res 2005;11:1044–1049. [PubMed]
  20. Tang J, Wu YM, Zhao P, et al. Overexpression of HAb18G/CD147 promotes invasion and metastasis via α3β1 integrin mediated FAK-paxillin and FAK-PI3K-Ca2+ pathways. Cell Mol Life Sci 2008;65: 2933–2942. [PubMed/NCBI]
  21. Tsubaki M, Satou T, Itoh T, et al. Reduction of metastasis, cell invasion, and adhesion in mouse osteosarcoma by YM529/ONO-5920-induced blockade of the Ras/MEK/ERK and Ras/PI3K/Akt pathway. Toxicol Appl Pharmacol 2012;259(3) 402–10. [PubMed]
  22. Neuzillet JM, Traynor C, Hullmann G, Tyritzis G, Shimizu J.TNF-α-induced IL-32 expression in esophageal cancer: cross talk JNK/Akt signaling pathways. American Journal of BioMedicine 2013;1(2):73-85. [Abstract/Full-Text]

Journal of cellular cancer picture

 

 

 

 

 

 

RJung Zhang, Kai-Li Feng,Ting Wang, Shan Young-Kyun, Liu Yan, Chung Tae-Young. Potential role of circulating miRNAs as biomarkers in solid tumor. Journal of cellular cancer 2014; 6(2):39-57.